Developer docs
API playgroundTry for free, no card

Search company profiles

BioVersys

Full company profile

uuid000078m

Namestring
BioVersys
Legal namestring
BioVersys AG
Websiteurl
bioversys.com
Company typeenum
Public
Founded yearint
2008
Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial resistance therapeutics, antibacterial drug development, multi-drug resistant infections, clinical-stage biopharmaceuticals, tuberculosis drug discovery
Industry3 codes
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAKAGAH
Tuberculosis & Mycobacterial Diseases
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Infectious Disease Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Revenue
TypeLicensing Royalties
Description

BioVersys is a pre-commercial clinical-stage biopharma company generating minimal revenue. FY2025 revenue was CHF 3.3 million (likely from collaborations/grants), with an operating loss of CHF 20 million. Revenue model will shift to pharmaceutical product sales following regulatory approval of BV100, alpibectir, and pipeline assets.

bioversys.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Strategic partnerships with GSK (alpibectir), Shionogi (BV500), and others generate milestone-based non-dilutive funding and future royalty streams. Shionogi collaboration includes potential milestone payments of up to CHF 479 million plus royalties for BV500 program. GSK has taken equity stake and co-funds Phase 2 development of alpibectir.

venturelab.swiss
3Non-Dilutive Funding (Grants)
TypeLicensing Royalties
Description

BioVersys secured significant non-dilutive funding from public and private organizations: IMI2 JU TRIC-TB grant (€6.92M), EDCTP grant (€2.7M), CARB-X awards (up to $8.92M for BV200, up to $15.34M for BV300), CF AMR Syndicate (up to GBP 500K), RespiriNTM EU program (up to €2M), Wellcome ADVANCE-ID network (CHF 14M), and GIBF investment (US$6M).

european-biotechnology.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BioVersys is a clinical-stage biopharmaceutical company developing novel small-molecule antibacterial drugs to treat serious life-threatening infections caused by multi-drug resistant bacteria. Its pipeline targets WHO and CDC priority pathogens including carbapenem-resistant Acinetobacter baumannii (CRAB), multidrug-resistant tuberculosis (MDR-TB), and non-tuberculous mycobacteria (NTM), using proprietary TRIC and Ansamycin Chemistry platforms. Lead asset BV100 (intravenous rifabutin) is in Phase 3; alpibectir is in Phase 2b with GSK.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • BV100 Phase 2: 50% relative reduction in 28-day all-cause mortality compared to best available therapy for CRAB infections
+4 more records
Product overview1 text field

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant bacteria. The company's pipeline consists of clinical and preclinical assets targeting WHO and CDC priority pathogens. Lead product BV100 (Phase 3) is an intravenous rifabutin formulation for carbapenem-resistant Acinetobacter baumannii infections. Alpibectir (Phase 2b) is a tuberculosis treatment potentiator developed with GSK. The company operates two technology platforms: TRIC (Transcriptional Regulator Inhibitory Compounds) and Ansamycin Chemistry. Other programs include BV200 (anti-virulence for S. aureus), BV300 (novel ribosome inhibitor for ESKAPE pathogens), and BV500 (NTM program with Shionogi partnership).

Product and service5 records
1BV100
CategoryAntibacterial Drug Candidate
Description

An innovative intravenous rifabutin formulation developed for multidrug-resistant bacterial infections, specifically targeting carbapenem-resistant Acinetobacter baumannii (CRAB) causing hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). It has a novel mode of action and has received QIDP designation from the US FDA. Currently in Phase 3 clinical trials.

2Alpibectir (BVL-GSK098)
CategoryAntibacterial Drug Candidate
Description

A transcriptional regulator inhibitory compound (TRIC) that reverses resistance and potentiates the activity of ethionamide and prothionamide for treating tuberculosis, including MDR-TB and TB meningitis. It is the first drug targeting bacterial transcriptional regulators to enter human clinical trials. In Phase 2b development.

3BV200
CategoryAntibacterial Drug Candidate
Description

A first-in-class anti-virulence small molecule that disarms Staphylococcus aureus bacteria (including MRSA) by abolishing toxin production, without inducing resistance. Being developed for atopic dermatitis and severe hospital infections. Currently in preclinical stage.

4BV300
CategoryAntibacterial Drug Candidate
Description

A novel chemical class of small molecules inhibiting an unexploited binding site on the bacterial ribosome. Exhibits robust coverage of all ESKAPE pathogens and biothreat pathogens. Currently in preclinical development.

5BV500
CategoryAntibacterial Research Program
Description

A research program addressing non-tuberculous mycobacteria (NTM) infections derived from the company's proprietary Ansamycin Chemistry platform. Targets bacterial RNA polymerase (RNAP) with multiple novel molecule series that overcome resistance mechanisms. Developed under global research collaboration with Shionogi.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Exclusive collaboration and license agreement to develop ansamycin antimicrobial candidates targeting non-tuberculous mycobacteria (NTM) diseases. Leverages BioVersys' Ansamycin Chemistry platform and HMH's Center for Discovery and Innovation. HMH eligible for payments and royalties. Partnership addresses NTM infections affecting ~250,000 people annually, particularly cystic fibrosis and COPD patients.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-01-01
Description

BioVersys (CEO Marc Gitzinger) has been selected for Swiss National Startup Team Venture Leaders program multiple times (2008, 2017, 2026). Program connects Swiss biotech startups with Tier 1 VCs through international roadshows (Boston 2026), helping accelerate US expansion.

3EU RespiriNTM Programme (IHI2)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-10-22
Description

BioVersys joined the EU-funded RespiriNTM programme (Innovative Health Initiative 2) with access to up to €2 million in non-dilutive funding for BV500 NTM program development. The 8-year program explores multiple approaches for anti-mycobacterial compounds and includes consortium partners with expertise in AMR. BioVersys leads development of its candidates through preclinical and clinical studies.

bioversys.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-06-04
Description

CF AMR Syndicate awarded up to GBP 500,000 in non-dilutive funding for BioVersys' NTM project targeting resistant non-tuberculous mycobacteria lung infections in people with cystic fibrosis. LifeArc, Medicines Discovery Catapult, and Cystic Fibrosis Trust provide complementary disease-specific support and expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-07
Description

Expanded strategic collaboration to accelerate clinical development of alpibectir (BVL-GSK098) for pulmonary and meningitis TB programs. GSK took an equity stake in BioVersys and participated in Series C financing extension of CHF 12.3M (total CHF 44.9M). Under UNITE4TB project (IMI2), GSK leads Phase 2b trial of AlpE in six African countries. BioVersys and GSK co-develop alpibectir for global registration.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-05-01
Description

Memorandum of Understanding signed May 2020 for GARDP to support BioVersys in preparing a pediatric investigational plan (PIP) for BV100. GARDP is a non-profit organization developing new antibiotics for public health needs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global research collaboration for BV500 program with potential milestone payments of up to CHF 479 million plus royalties. BioVersys' BV500 NTM candidates are developed under this partnership targeting non-tuberculous mycobacteria pulmonary diseases. Shionogi collaboration follows successful ansamycin platform development at BioVersys.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Wellcome is funding the ADVANCE-ID Phase 2b clinical trial network with CHF 14 million to evaluate BV100 for multidrug-resistant bacterial infections in Southeast Asia. The trial will enroll patients primarily in Southeast Asia across 35 countries with an expanded cohort of 90 patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration partner in the discovery and development of BVL-GSK098 (alpibectir) using the TRIC technology platform. Institut Pasteur de Lille contributed to the identification of the TRIC technology and continues as a key academic partner in the TRIC-TB consortium.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner in TRIC-TB consortium contributing to the discovery of BVL-GSK098 (alpibectir). Part of the public-private partnership that developed the TRIC technology platform for TB drug discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research organization and consortium partner conducting the bEto-TB Phase 2a trial of alpibectir in South Africa. TASK has been a key partner in the execution of the TB clinical development program in South Africa.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Entasis (acquired by Innoviva) developed sulbactam-durlobactam (XACDURO), the first FDA-approved antibiotic specifically for carbapenem-resistant Acinetobacter baumannii (CRAB) infections — a direct competitor to BioVersys' BV100 in the same CRAB hospital pneumonia indication. Most directly comparable peer.

TypeDirect peer
Description

Clinical-stage antibacterial company developing novel therapies against MDR Gram-negative pathogens including cefepime-taniborbactam for complicated UTIs and other resistant infections. Comparable in stage, modality (small-molecule anti-infectives), and AMR focus.

TypeDirect peer
Description

Clinical-stage antibiotic developer focused on sulopenem for multi-drug resistant infections including complicated UTIs. Comparable clinical-stage profile and AMR positioning, though different therapeutic indication.

TypeDirect peer
Description

Swiss clinical-stage biopharmaceutical company developing antibiotics for MDR Gram-negative infections (murepavadin) and rare diseases. Closest geographic and historical peer — multiple BioVersys executives previously worked at Polyphor/Spexis.

TypeDirect peer
Description

Specialty biopharmaceutical company developing antibiotics including Nuzyra (omadacycline) for community-acquired pneumonia and skin infections. Comparable AMR-focused commercial/specialty antibiotics profile.

TypeBroad incumbent
Description

Global biopharmaceutical major with a major anti-infectives franchise. Direct partner (and equity holder) of BioVersys for alpibectir development, with deep antibiotic R&D, commercialization, and global health access infrastructure. Comparable as both partner and incumbent in same therapeutic space.

TypeBroad incumbent
Description

Japanese multinational pharmaceutical company with a leading global antibiotics franchise (cefiderocol/Fetcroja). Partner to BioVersys for the BV500 NTM program (up to CHF 479M in potential milestones). Comparable as both strategic partner and direct incumbent in antibacterial drug development.

TypeDirect peer
Description

Clinical-stage biotechnology company developing novel anti-infectives, including rezafungin (approved for candidemia/invasive candidiasis) and Cloudbreak antiviral conjugates. Comparable clinical-stage anti-infective business model and modality mix.

9Nabriva Therapeutics
TypeDirect peer
Description

Biopharmaceutical company focused on commercializing antibiotics including XENLETA (lefamulin) for community-acquired bacterial pneumonia. Comparable specialty antibiotics profile targeting MDR respiratory pathogens.

TypeOthers
Description

Antibiotic-focused specialty pharma (Baxdela/delafloxacin) that emerged from Chapter 11 bankruptcy in 2020. Relevant as a cautionary benchmark for AMR commercial dynamics — illustrates the structural challenge BioVersys could face at commercialization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioVersys

Infectious Disease Therapeuticsbioversys.com

BioVersys firmographics

Firmographics
Name
BioVersys
Legal name
BioVersys AG
Website
https://bioversys.com
Company type
Public
Founded year
2008
Operating status
Ipo
Headcount range
11–50 employees
Ownership category
akta.pro rank

BioVersys industry classification

Industry
Product category
Infectious Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAKAGAH
Tuberculosis & Mycobacterial Diseases
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antimicrobial resistance therapeutics
  • Antibacterial drug development
  • Multi-drug resistant infections
  • Clinical-stage biopharmaceuticals
  • Tuberculosis drug discovery

Where BioVersys is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

BioVersys business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Revenue: BioVersys is a pre-commercial clinical-stage biopharma company generating minimal revenue. FY2025 revenue was CHF 3.3 million (likely from collaborations/grants), with an operating loss of CHF 20 million. Revenue model will shift to pharmaceutical product sales following regulatory approval of BV100, alpibectir, and pipeline assets.
  2. Licensing and Milestone Payments: Strategic partnerships with GSK (alpibectir), Shionogi (BV500), and others generate milestone-based non-dilutive funding and future royalty streams. Shionogi collaboration includes potential milestone payments of up to CHF 479 million plus royalties for BV500 program. GSK has taken equity stake and co-funds Phase 2 development of alpibectir.
  3. Non-Dilutive Funding (Grants): BioVersys secured significant non-dilutive funding from public and private organizations: IMI2 JU TRIC-TB grant (€6.92M), EDCTP grant (€2.7M), CARB-X awards (up to $8.92M for BV200, up to $15.34M for BV300), CF AMR Syndicate (up to GBP 500K), RespiriNTM EU program (up to €2M), Wellcome ADVANCE-ID network (CHF 14M), and GIBF investment (US$6M).

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

BioVersys product offering

Product offering

Core offering

BioVersys is a clinical-stage biopharmaceutical company developing novel small-molecule antibacterial drugs to treat serious life-threatening infections caused by multi-drug resistant bacteria. Its pipeline targets WHO and CDC priority pathogens including carbapenem-resistant Acinetobacter baumannii (CRAB), multidrug-resistant tuberculosis (MDR-TB), and non-tuberculous mycobacteria (NTM), using proprietary TRIC and Ansamycin Chemistry platforms. Lead asset BV100 (intravenous rifabutin) is in Phase 3; alpibectir is in Phase 2b with GSK.

Product overview

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant bacteria. The company's pipeline consists of clinical and preclinical assets targeting WHO and CDC priority pathogens. Lead product BV100 (Phase 3) is an intravenous rifabutin formulation for carbapenem-resistant Acinetobacter baumannii infections. Alpibectir (Phase 2b) is a tuberculosis treatment potentiator developed with GSK. The company operates two technology platforms: TRIC (Transcriptional Regulator Inhibitory Compounds) and Ansamycin Chemistry. Other programs include BV200 (anti-virulence for S. aureus), BV300 (novel ribosome inhibitor for ESKAPE pathogens), and BV500 (NTM program with Shionogi partnership).

Differentiator

Problem solved

Functional benefit

Products and services

  • BV100 An innovative intravenous rifabutin formulation developed for multidrug-resistant bacterial infections, specifically targeting carbapenem-resistant Acinetobacter baumannii (CRAB) causing hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). It has a novel mode of action and has received QIDP designation from the US FDA. Currently in Phase 3 clinical trials.
  • Alpibectir (BVL-GSK098) A transcriptional regulator inhibitory compound (TRIC) that reverses resistance and potentiates the activity of ethionamide and prothionamide for treating tuberculosis, including MDR-TB and TB meningitis. It is the first drug targeting bacterial transcriptional regulators to enter human clinical trials. In Phase 2b development.
  • BV200 A first-in-class anti-virulence small molecule that disarms Staphylococcus aureus bacteria (including MRSA) by abolishing toxin production, without inducing resistance. Being developed for atopic dermatitis and severe hospital infections. Currently in preclinical stage.
  • BV300 A novel chemical class of small molecules inhibiting an unexploited binding site on the bacterial ribosome. Exhibits robust coverage of all ESKAPE pathogens and biothreat pathogens. Currently in preclinical development.
  • BV500 A research program addressing non-tuberculous mycobacteria (NTM) infections derived from the company's proprietary Ansamycin Chemistry platform. Targets bacterial RNA polymerase (RNAP) with multiple novel molecule series that overcome resistance mechanisms. Developed under global research collaboration with Shionogi.

Quantifiable outcome

  • BV100 Phase 2: 50% relative reduction in 28-day all-cause mortality compared to best available therapy for CRAB infections
  • +4 more outcomes

Companies that use BioVersys

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

BioVersys technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BioVersys partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered major, minor and core.

  • Hackensack Meridian Health (HMH)majorStrategic or Co-development Partner · 31 March 2026Exclusive collaboration and license agreement to develop ansamycin antimicrobial candidates targeting non-tuberculous mycobacteria (NTM) diseases. Leverages BioVersys' Ansamycin Chemistry platform and HMH's Center for Discovery and Innovation. HMH eligible for payments and royalties. Partnership addresses NTM infections affecting ~250,000 people annually, particularly cystic fibrosis and COPD patients.
  • Venturelab (Venture Leaders)minorGTM or Marketing Partner · 1 January 2026BioVersys (CEO Marc Gitzinger) has been selected for Swiss National Startup Team Venture Leaders program multiple times (2008, 2017, 2026). Program connects Swiss biotech startups with Tier 1 VCs through international roadshows (Boston 2026), helping accelerate US expansion.
  • EU RespiriNTM Programme (IHI2)majorStrategic or Co-development Partner · 22 October 2024BioVersys joined the EU-funded RespiriNTM programme (Innovative Health Initiative 2) with access to up to €2 million in non-dilutive funding for BV500 NTM program development. The 8-year program explores multiple approaches for anti-mycobacterial compounds and includes consortium partners with expertise in AMR. BioVersys leads development of its candidates through preclinical and clinical studies.
  • CF AMR Syndicate (LifeArc, Medicines Discovery Catapult, Cystic Fibrosis Trust)majorStrategic or Co-development Partner · 4 June 2024CF AMR Syndicate awarded up to GBP 500,000 in non-dilutive funding for BioVersys' NTM project targeting resistant non-tuberculous mycobacteria lung infections in people with cystic fibrosis. LifeArc, Medicines Discovery Catapult, and Cystic Fibrosis Trust provide complementary disease-specific support and expertise.
  • GSK (GlaxoSmithKline)coreStrategic or Co-development Partner · 7 May 2024Expanded strategic collaboration to accelerate clinical development of alpibectir (BVL-GSK098) for pulmonary and meningitis TB programs. GSK took an equity stake in BioVersys and participated in Series C financing extension of CHF 12.3M (total CHF 44.9M). Under UNITE4TB project (IMI2), GSK leads Phase 2b trial of AlpE in six African countries. BioVersys and GSK co-develop alpibectir for global registration.
  • Global Antibiotic Research and Development Partnership (GARDP)majorStrategic or Co-development Partner · 1 May 2020Memorandum of Understanding signed May 2020 for GARDP to support BioVersys in preparing a pediatric investigational plan (PIP) for BV100. GARDP is a non-profit organization developing new antibiotics for public health needs.
  • Shionogi & Co., Ltd.coreStrategic or Co-development PartnerGlobal research collaboration for BV500 program with potential milestone payments of up to CHF 479 million plus royalties. BioVersys' BV500 NTM candidates are developed under this partnership targeting non-tuberculous mycobacteria pulmonary diseases. Shionogi collaboration follows successful ansamycin platform development at BioVersys.
  • WellcomemajorStrategic or Co-development PartnerWellcome is funding the ADVANCE-ID Phase 2b clinical trial network with CHF 14 million to evaluate BV100 for multidrug-resistant bacterial infections in Southeast Asia. The trial will enroll patients primarily in Southeast Asia across 35 countries with an expanded cohort of 90 patients.
  • Institut Pasteur de LillecoreStrategic or Co-development PartnerCollaboration partner in the discovery and development of BVL-GSK098 (alpibectir) using the TRIC technology platform. Institut Pasteur de Lille contributed to the identification of the TRIC technology and continues as a key academic partner in the TRIC-TB consortium.
  • University of LillecoreStrategic or Co-development PartnerAcademic partner in TRIC-TB consortium contributing to the discovery of BVL-GSK098 (alpibectir). Part of the public-private partnership that developed the TRIC technology platform for TB drug discovery.
  • TASK (South Africa)coreStrategic or Co-development PartnerClinical research organization and consortium partner conducting the bEto-TB Phase 2a trial of alpibectir in South Africa. TASK has been a key partner in the execution of the TB clinical development program in South Africa.

Scale indicators12 records

Recent moves8 records

Expansion highlights7 records

BioVersys competitors and assessment

Company assessment

Direct peers

  • Entasis Therapeutics: Entasis (acquired by Innoviva) developed sulbactam-durlobactam (XACDURO), the first FDA-approved antibiotic specifically for carbapenem-resistant Acinetobacter baumannii (CRAB) infections — a direct competitor to BioVersys' BV100 in the same CRAB hospital pneumonia indication. Most directly comparable peer.
  • VenatoRx Pharmaceuticals: Clinical-stage antibacterial company developing novel therapies against MDR Gram-negative pathogens including cefepime-taniborbactam for complicated UTIs and other resistant infections. Comparable in stage, modality (small-molecule anti-infectives), and AMR focus.
  • Iterum Therapeutics: Clinical-stage antibiotic developer focused on sulopenem for multi-drug resistant infections including complicated UTIs. Comparable clinical-stage profile and AMR positioning, though different therapeutic indication.
  • Spexis AG (formerly Polyphor): Swiss clinical-stage biopharmaceutical company developing antibiotics for MDR Gram-negative infections (murepavadin) and rare diseases. Closest geographic and historical peer — multiple BioVersys executives previously worked at Polyphor/Spexis.
  • Paratek Pharmaceuticals: Specialty biopharmaceutical company developing antibiotics including Nuzyra (omadacycline) for community-acquired pneumonia and skin infections. Comparable AMR-focused commercial/specialty antibiotics profile.
  • Cidara Therapeutics: Clinical-stage biotechnology company developing novel anti-infectives, including rezafungin (approved for candidemia/invasive candidiasis) and Cloudbreak antiviral conjugates. Comparable clinical-stage anti-infective business model and modality mix.
  • Nabriva Therapeutics: Biopharmaceutical company focused on commercializing antibiotics including XENLETA (lefamulin) for community-acquired bacterial pneumonia. Comparable specialty antibiotics profile targeting MDR respiratory pathogens.

Broad incumbents

  • GSK: Global biopharmaceutical major with a major anti-infectives franchise. Direct partner (and equity holder) of BioVersys for alpibectir development, with deep antibiotic R&D, commercialization, and global health access infrastructure. Comparable as both partner and incumbent in same therapeutic space.
  • Shionogi & Co., Ltd. Japanese multinational pharmaceutical company with a leading global antibiotics franchise (cefiderocol/Fetcroja). Partner to BioVersys for the BV500 NTM program (up to CHF 479M in potential milestones). Comparable as both strategic partner and direct incumbent in antibacterial drug development.

Others

  • Melinta Therapeutics: Antibiotic-focused specialty pharma (Baxdela/delafloxacin) that emerged from Chapter 11 bankruptcy in 2020. Relevant as a cautionary benchmark for AMR commercial dynamics — illustrates the structural challenge BioVersys could face at commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights6 records

Customer concentration

BioVersys social profiles

Digital presence

BioVersys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioVersys leadership team

Management profile

Number of profiles

Profiles12 records

BioVersys subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

BioVersys funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioVersys M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioVersys

What does BioVersys do?

BioVersys is a clinical-stage biopharmaceutical company developing novel small-molecule antibacterial drugs to treat serious life-threatening infections caused by multi-drug resistant bacteria. Its pipeline targets WHO and CDC priority pathogens including carbapenem-resistant Acinetobacter baumannii (CRAB), multidrug-resistant tuberculosis (MDR-TB), and non-tuberculous mycobacteria (NTM), using proprietary TRIC and Ansamycin Chemistry platforms. Lead asset BV100 (intravenous rifabutin) is in Phase 3; alpibectir is in Phase 2b with GSK.

Is BioVersys a public or private company?

BioVersys is a public company. It is classified as public and is currently ipo.

When was BioVersys founded?

BioVersys was founded in 2008. It employs 11 to 50 people.

Where is BioVersys based?

BioVersys is headquartered in Basel, Switzerland, in the Europe region.

How does BioVersys make money?

Three revenue lines are on record. Pharmaceutical Product Revenue is the primary driver. The others are licensing and Milestone Payments and non-Dilutive Funding (Grants).

Who are BioVersys's main competitors?

Direct peers on record are Entasis Therapeutics, VenatoRx Pharmaceuticals, Iterum Therapeutics, Spexis AG (formerly Polyphor), Paratek Pharmaceuticals, Cidara Therapeutics and Nabriva Therapeutics. Broad incumbents are GSK and Shionogi & Co., Ltd.. Melinta Therapeutics is listed as an others.

Does BioVersys have an API?

No public API is recorded for BioVersys.

What industry is BioVersys in?

BioVersys's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAKAGAH, Tuberculosis & Mycobacterial Diseases. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooBioVersys and Partners to Present AlpE data at The Union World Conference on Lung HealthBioVersys will present new data on alpibectir with GSK at the Union World Conference on Lung Health in Rio de Janeiro, November 17-20, 2026. The presentations cover Phase 2 data on alpibectir-ethionamide in newly diagnosed drug-sensitive pulmonary tuberculosis, including early bactericidal activity and safety.Business & FinancialBioversys Announces Publication Of BV100 Lung Penetration And Drug Interaction Data In Two Leading Peer-Reviewed Antimicrobial JournalsBioversys published two Phase 1 studies of BV100 in peer-reviewed journals, showing lung fluid and alveolar macrophage concentrations 35- and over 300-fold higher than plasma, and a mild CYP3A interaction profile. The data support BV100's use in severe CRAB pneumonia, with ongoing Phase 3 RIV-TARGET trial enrollment and topline data expected in early 2028.FinanzNachrichten.deBioversys weitet Verlust zum Halbjahr aus - Finanziert bis 2028Bioversys reported a loss in the first half of 2026, with all pipeline candidates still in research. The Basel biotech firm expects to be funded until 2028 and anticipates a smaller loss for 2026. Operational revenue for the half-year was 2 million Swiss francs.MarketScreenerBioVersys Wins US FDA Fast Track Designation for Lead Clinical Asset BV100BioVersys AG received US FDA fast track designation for its lead clinical asset BV100, a small-molecule antibacterial. The compound targets carbapenem-resistant Acinetobacter baumannii (CRAB) lung and bloodstream infections in intensive care patients, aiming to reduce mortality where current treatments fail.FinanzNachrichten.deBioVersys AG: BioVersys to report its half-year 2026 financial results, provide a business update and host a conference callBioVersys AG, a Swiss clinical-stage biopharmaceutical company developing antibacterial products against multi-drug resistant bacteria, announced it will report its half-year 2026 financial results on September 9, 2026. The company will issue a press release at 7:00 AM CET and host a conference call and webcast at 2:00 PM CET, where management will review results, provide a business update and outline its strategic outlook.SWI swissinfo.chBasel’s world-beating pharma hub fights for place in new global orderBasel, home to Roche and Novartis, is competing to retain its pharmaceutical hub status amid AI, geopolitics, and new rivals. The region has 800 life sciences companies and attracted CHF572.3 million in venture capital in 2025, but Roche and Novartis are investing $73 billion in the US to avoid tariffs. Basel's federal government must address national pharma strategy.PR NewswirePneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsightThe pneumonia treatment market is projected to grow through 2036, with the United States leading in 2025. Growth is driven by an aging population, rising chronic disease burden, and emerging therapies like Tosatoxumab and AON-D21. The report covers the 7MM from 2022 to 2036.European BiotechnologySwitzerland’s biotech sector defies tough markets with record revenueSwitzerland's biotech industry achieved record revenue of CHF 7.5 billion in 2025, up from CHF 7.2 billion the previous year, driven by growing market-ready products and strong demand for specialized CDMO services. Private financing reached CHF 1.15 billion, a 38% increase, with Windward Bio raising CHF 186 million and GlycoEra securing CHF 104 million, while BioVersys completed Europe's largest IPO of 2025 in Switzerland. Employment in the sector reached a record high of over 21,000 full-time positions, with Roche CEO Thomas Schinecker emphasizing at Swiss Biotech Day that Switzerland must remain relevant in global pharma markets.Greater Geneva Bern area (GGBa)Swiss Biotech Report : talent and tenacity drive record performanceThe Swiss Biotech Report 2026 shows Switzerland's biotech sector achieved record revenues of CHF 7.5 billion and employed over 21,000 full-time workers in 2025, despite ongoing challenges in global public capital markets. Swiss biotech companies raised CHF 2.6 billion in total financing, with private funding reaching a record CHF 1.15 billion, up 38% from 2024 and representing 45% of total sector financing. Notable transactions include BioVersys' CHF 80 million IPO on SIX Swiss Exchange (Europe's largest biotech IPO in five years), a CHF 479 million research collaboration between BioVersys and Shionogi, and a USD 456 million licensing agreement between CDR-Life and Boehringer Ingelheim.YahooBioVersys Announces Approval of all Board Proposals at Annual General Meeting of ShareholdersBioVersys AG announced that its shareholders approved all board proposals at the Annual General Meeting held on April 30, 2026. The approval included the re-election of the Board of Directors and the appointment of new member Simona Skerjanec, alongside the adoption of the 2025 annual report and financial statements. The company highlighted its ongoing focus on the global Phase 3 trial for BV100 and collaboration with GlaxoSmithKline for alpibectir.